Strategic Investment Overview
Cohance Lifesciences Limited announced two proposed transactions totaling USD 18 million to strengthen its Antibody-drug Conjugate (ADC) strategy. The investments will be funded entirely through internal accruals.
NJ Bio Investment Details
- Investment Amount: USD 13 million additional investment
- Ownership Change: Increases common-equity ownership from 56.0% to 67.3%
- Sellers: Acquires entire holdings of Ms. Priyashri Nayak and the Jain Family Irrevocable Trust
- Remaining Ownership: Dr. Jain will retain 32.7% ownership
- Leadership: Dr. Jain will continue to lead NJ Bio while also advancing Aruka's pipeline
Aruka Bio Investment Details
- Investment Amount: USD 5 million equity investment
- Purpose: Funds buyout of other existing shareholders and convertible noteholders along with working capital
- Ownership Structure Post-Investment:
- 65% directly by Cohance
- 25% by NJ Bio
- 10% by Dr. Jain
- Note: These percentages are before further dilution from Dr. Jain's performance-linked equity award
Strategic Rationale
The reorganization establishes distinct priorities:
1. Deeper integration of NJ Bio's customer-facing services with Cohance
2. Focused development of Aruka's proprietary pipeline through potential partnerships
NJ Bio will remain focused on customer-facing contract research, development and manufacturing services (CRDMO). Closer integration will combine NJ Bio's payload-linker and bioconjugation expertise with Cohance's manufacturing capabilities to support customers end-to-end from development through commercial supply.
Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates with its lead program currently at the preclinical stage. The investment consolidates control of Aruka's proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners.
Background and Timing
This follows a review of NJ Bio's performance and integration with Cohance since the original investment in December 2024. The review identified an opportunity to strengthen commercial alignment between the two businesses as NJ Bio expands its GMP CDMO services and to give dedicated leadership focus to Aruka's novel drug development pipeline.
Expected Completion
Completion is expected by the end of September 2026, subject to:
- Definitive agreements
- Applicable approvals
- Customary closing conditions
Management Commentary
Dr. Naresh Jain, Founder and CEO, NJ Bio: "I will work across both businesses supporting NJ Bio's growth and an orderly leadership handover, while working together with Cohance in advancing Aruka's pipeline and exploring development partnerships. Thereafter, I will focus full-time on Aruka as CEO, while continuing to support NJ Bio as a strategic advisor."
Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences: "This reorganisation gives each business a clear focus: strengthening NJ Bio's customer offering through closer integration with Cohance and creating the opportunity for Dr Jain to lead Aruka's next phase. This integration is expected to strengthen business performance across the combined platform over time."
Company Background
Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. The company leverages a combined platform with state-of-the-art facilities in India and the U.S., delivering integrated solutions from early development to commercial supply for leading global pharma companies.